Skip to main content
. 2021 Mar 18;11:6328. doi: 10.1038/s41598-021-85948-2

Figure 2.

Figure 2

Overall survival according to baseline levels (A) ALC, (B) NLR, (C) PLR, and (D) LMR in patients treated with paclitaxel plus bevacizumab. ALC absolute lymphocyte count, CI confidence interval, LMR lymphocyte-to-monocyte ratio, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio.